Skip to Main Content
Services Talent Knowledge
Site Search
Menu

Events

April 23, 2018

ACI's Hatch-Waxman Series: 12th Annual Paragraph IV Disputes

Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.

As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.

  1. A U.S. DISTRICT COURT JUDGES' ROUNDTABLE with the Chief Judges from Delaware, The Northern District of Illinois and New Jersey
    • Do not miss your opportunity to hear directly from
    • Chief Judges Castillo, Linares, and Stark
  2. TC HEARTLAND THINK TANK
    • Top litigators and leading in house counsel will brainstorm with you on venue and jurisdictional strategies in the aftermath of TC Heartland
  3. FOCUS GROUP ON OIL STATES AND SAS
    • You will have the opportunity to hear from those "in the know" as well as join the discussion on these two pivotal pending Supreme Court decisions and their possible consequences on the future of IPRs
  4. 4 FTC KEYNOTE
    • Markus Meier will provide insights on the latest anti-trust developments affecting Paragraph IV litigation
  5. TWO NEW CONFERENCE TRACKS that will contemplate:
    • The Business of Pharmaceutical Patent Litigation; and
    • The Practice of Pharmaceutical Patent Litigation

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks